뉴스

NEWS

ASCO 채택된 KCSG 연구결과: 2024 ASCO Annual Meeting

2024 ASCO* Annual Meeting에서 KCSG에서 공동으로 수행한 연구 결과가 10건 채택되어 발표되었습니다! ASCO 속에 KCSG를 만나보세요!

* ASCO: 미국임상암학회 (American Society of Clinical Oncology)

KCSG BR15-01 : A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.
KCSG BR15-10 : Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.
KCSG GU20-03 : A multicenter phase II study of modified FOLFIRINOX for first-line treatment for advanced urachal cancer (ULTMA; KCSG GU20-03).
KCSG HN18-07 : A phase II trial of neoadjuvant docetaxel/5-FU/cisplatin in combination with prophylactic pegteograstim in unresectable, locally advanced nasal cavity/paranasal squamous cell carcinoma: KCSG HN18-07.
KCSG UN18-15 : Phase II trial, multicenter, first line paclitaxel-avelumab treatment for inoperable angiosarcoma.
KCSG BR21-15 : Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15).
KCSG AL22-09 : Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).
KCSG AL19-17 : ctDNA as a biomarker in phase II study of tepotinib in advanced solid cancers with MET exon 14 skipping mutation or amplification (KCSG AL19-17).
KCSG AL20-17 : Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17).
KCSG PC22-11 : Comparison of prophylactic effects for chemotherapy-induced neutropenia between same-day vs next-day administration of pegteograstim in chemotherapy regimen composed of day 1 intensive myelosuppressive agent: A randomized phase III trial (CONCISE, KCSG PC22-11).

KCSG 회원의 소식을 전해드립니다

회원님들의 근황 및 연구회 소식 전달을 위한 내용을 접수 받고 있습니다. 보다 풍성한 뉴스레터가 되기 위해 여러 회원님의 참여를 기다리고 있습니다. 연구회 회원분들과 공유하고 싶으신 내용을 아래 메일로 보내주세요! E-mail. jyhan@kcsg.org

Korean Cancer Study Group

Webzine Vol.32 JUNE 2024

NEWS

ASCO 채택된 KCSG 연구결과: 2024 ASCO Annual Meeting

KCSG 회원의 소식을 전해드립니다